Update on FDG-PET in pediatric lymphoma

Lymphoma represent the third most common malignant disease in childhood and adolescence. They are divided into pediatric Hodgkin lymphoma (P -HL) and pediatric non -Hodgkin lymphoma (P -NHL). In P -HL, excellent cure rates are achieved through combined modality treatment using chemotherapy and radiotherapy. For more than 20 years, FDG-PET has been an integral part of the treatment and guides its intensity through improved staging and precise assessment of chemotherapy response. In P -NHL, good cure rates are achieved with chemotherapy alone. At present FDG-PET plays only a subordinate role in the treatment setting. Its potential to contribute to treatment management is far from being fully utilised. In this article, the current status of FDG-PET in pediatric lymphoma is presented in detail. The core elements are the sections on staging and response assessment. In addition, challenges and pitfalls are discussed and future developments are outlined. (Cite this article as: Kurch L, Kluge R. Update on FDG-PET in pediatric lymphoma. Q J Nucl Med Mol Imaging 2024;68:58-69. DOI: 10.23736/ S1824 -4785.24.03560-X)